Back to Search
Start Over
A Day 14 Endpoint for Acute Gvhd Clinical Trials
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p779-779, 1p
- Publication Year :
- 2023
-
Abstract
- The overall response rate (ORR) 28 days (D28) after treatment has been adopted as the primary endpoint for clinical trials of acute graft versus host disease (GVHD). ORR combines complete response (CR) and partial response (PR) because CR and PR have very similar non relapse mortality (NRM). D28 ORR has some disadvantages: first, physicians usually decide to modify immunosuppression much earlier than D28, and second, NRM does not always correlate well with ORR at D28, particularly for patients who present with intermediate risk or low risk disease.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64589286
- Full Text :
- https://doi.org/10.1182/blood-2023-172955